placeholder
Importance
62
Trust
70
Urgency
30
REGULATORY · PRIMARY SOURCE
OrderlyMeds LLC dba OrderlyMeds - 728291 - 06/08/2026
The FDA warned OrderlyMeds, a compounding pharmacy, that it made false claims about selling weight-loss drugs like semaglutide and tirzepatide. The company falsely said it was an FDA-licensed pharmacy and put its logo on drug labels it didn't actually make.
Analysis
FDA keeps cracking down on compounders selling fake-branded semaglutide and tirzepatide. Fewer shady compounders means more patients pushed toward Novo and Lilly brand-name drugs.
- FDA issued warning letter MARCS-CMS 728291 to OrderlyMeds LLC, Decatur GA, on June 8, 2026
- OrderlyMeds falsely claimed its compounded drugs came from an 'FDA-licensed pharmacy'
- OrderlyMeds placed its own logo on drug labels for products it did not actually compound
FDA Drug Approvals & Databases4d
Read